Summit Therapeutics Initiates Global Phase II/III Harmoni-Gu1 Trial Of Ivonescimab In Bladder Cancer
SMMT•Trial initiation announced
-
Summitt Therapeutics Inc. SMMT.O:
-
Summit Therapeutics initiates global Phase II/III HARMONI-GU1 trial of ivonescimab in bladder cancer.
